KRAS and neoplasm: A recent study characterized the cellular proteomic and phosphoproteomic landscapes of KRAS-mutant tumor cell lines from a combined set of lung, pancreatic adenocarcinoma, and colorectal tumors and identified the therapeutic potential of specific cell subsets 22.